丙型肝炎病毒CTL-Th表位嵌合DNA疫苗的构建

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (10258 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To construct hepatitis C virus (HCV) CTL-Th epitopes chimeric DNA vaccine and explore its in vivo immune response. Methods: Based on previously identified four HCV-specific HLA-A*0201-restricted CTL (Cytotoxic T Lymphocyte) epitopes (NS4b_78, NS5a_367, C_181 and NS2_172), two HLA-A*1101-restricted CTL epitopes (NS3_609 and NS5b_251), one HLA-A*2402-restricted CTL epitopes (NS5b_382) and two Th epitopes (P73-15 and NS5A276-288), the gene encoding chimeric CTL epitopes and Th epitopes was synthesized and cloned into eukaryotic expressing vector pcDNATM3.1/myc-His(-) A. The recombinant plasmid was used to immunize HLA-A*0201, HLA-A*1101 and HLA-A*2402 transgenic mice, ELISPOT and CTL cytotoxicity assay were used to measure the frequencies of CTL epitope-specific T cells in splenocytes of mice and the cytotoxic activity of CTL against target cells. Results: The gene containing Kozak sequence and encoding Igκ chain signal sequence, seven CTL epitopes, two Th epitopes was successfully cloned into eukaryotic expressing vector. Recombinant plasmid immunization elicited epitope-specific IFN-γ-secreting T cells which could lyse CTL epitope-pulsed splenocytes. Conclusion: A Hepatitis C virus CTL-Th epitopes chimeric DNA vaccine which can induce epitope-specific CTL response is successfully constructed.

Key words： hepatitis C virus cytotoxicity T lymphocyte epitope DNA vaccine mice

Received: 11 October 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Dezhou1
	DUAN Zhiliang2
	GUO Jianglong2
	WANG Sina2
	LIU Huifang2
	WANG Zhibin2
	ZHONG Xiaozhi2
	CHEN Yongping3
	WEN

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I2/79

[1] Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle-An update[J]. J Hepatol, 2014, 61(1S): S3-S13.
[2] Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections[J]. J Hepatol, 2014, 61(S): S14-S25.
[3] 段志良, 张丽芳, 张琴, 等. 丙型肝炎病毒CTL表位的HLA-A2限制性及其免疫学效应研究[J]. 中华微生物学和免疫学杂志, 2009, 29(9): 822-826.
[4] 陈俊, 段志良, 巩文词, 等. 人白细胞抗原-A*0201限制性丙型肝炎病毒细胞毒性T淋巴细胞表位的鉴定[J]. 中华传染病杂志, 2010, 28(11): 651-655.
[5] 钟晓芝, 段志良, 郭江龙, 等. 丙型肝炎病毒HLA-A*1101和A*2402限制性CD8+T细胞表位的研究[J]. 温州医科大学学报, 2014, 44(8): 547-554.
[6] Wei H, Lenz SD, Thompson DH, et al. DNA-vaccine platform development against H1N1 subtype of swine influenza A viruses[J]. Viral Immunol, 2012, 25(4): 297-305.
[7] Hayashi A, Wakita H, Yoshikawa T, et al. A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity[J]. J Control Release, 2007, 117: 11-19.
[8] Polakova I, Duskova M, Smahel M. Antitumor DNA vaccination against the Sox2 transcription factor[J]. Int J Oncol,2014, 45(1): 139-146.
[9] Kesmir C, Nussbaum A, Schild H, et al. Prediction of proteasome cleavage motifs by neural network[J]. Prot Eng, 2002, 15: 287-296.
[10] Memarnejadian A, Roohvand F, Arashkia A, et al. Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice[J]. Protein Pept Lett, 2009, 16(7): 842-850.
[11] Memarnejadian A, Roohvand F. Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine[J]. Cell Immunol, 2010, 261(2): 93-98.
[12] Shi L, Liu S, Fan GX, et al. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C viruscytotoxic T lymphocyte epitopes[J]. Viral Immunol, 2006, 19(4): 702-711.